Factors affecting relapse rate in patients with neuromyelitis optica spectrum disorder

Affiliations

¹ Anne Rowling Regenerative Neurology Clinic, Chancellor's Building, University of Edinburgh, Edinburgh EH16 4SB, UK. Electronic address: fraser@tonnard.co.uk.

Comment

Fraser S Brown. Lancet Neurol. 2020 Jul.

. 2020 Jul;19(7):564.

doi: 10.1016/S1474-4422(20)30184-8.

¹ Anne Rowling Regenerative Neurology Clinic, Chancellor's Building, University of Edinburgh, Edinburgh EH16 4SB, UK. Electronic address: fraser@tonnard.co.uk.

No abstract available

Comment in

Factors affecting relapse rate in patients with neuromyelitis optica spectrum disorder - Authors' reply.
Tahara M, Oeda T, Sawada H. Tahara M, et al. Lancet Neurol. 2020 Jul;19(7):564. doi: 10.1016/S1474-4422(20)30185-X. Lancet Neurol. 2020. PMID: 32562675 No abstract available.

Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Tahara M, et al. Lancet Neurol. 2020 Apr;19(4):298-306. doi: 10.1016/S1474-4422(20)30066-1. Epub 2020 Mar 18. Lancet Neurol. 2020. PMID: 32199095 Clinical Trial.